GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Valuation Rank

Inoviq (ASX:IIQ) Valuation Rank


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Inoviq Valuation Rank Related Terms

Thank you for viewing the detailed overview of Inoviq's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Inoviq (ASX:IIQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Valuation Rank
Comparable Companies
ASX:CTE ASX:BDX ASX:LDX ASX:RHY ASX:GTG ASX:MAP ASX:IBX ASX:GSS TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN LH SHSE:603259
Traded in Other Exchanges
EGQ0:Germany
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Website
https://www.bard1.com
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.